OKYO Pharma (NASDAQ: OKYO) Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosing Statistically significant improvement was observed in both a “sign” (total conjunctival staining) and two “symptoms” (burning/stinging and blurred vision), endpoints of Dry Eye Disease A clear and informed path now established for further development of drug […]

Amesite Inc. (NASDAQ: AMST) Partners with Central Michigan University to Launch a Pioneering Asynchronous Implicit Bias Course for Healthcare Professionals

DETROIT, Jan. 04, 2024 (GLOBE NEWSWIRE) — Amesite Inc. (NASDAQ: AMST), a leading artificial intelligence software company offering a cloud-based learning platform for business and education markets, announces the launch of a new asynchronous Implicit Bias course tailored for healthcare professionals. This course is the result of a partnership between Amesite and CMU’s College of Medicine, along […]

Trio Petroleum Corp (NYSE American: TPET) Announces the Restart of the McCool Ranch Oil Field

Oilfield Fully-Permitted to Restart Production from Six Previously Producing Wells San Ardo Water Disposal Well WD-1 Successfully Refurbished and the Testing and Repairs of On-Site Facilities In-Progress Bakersfield, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) — Trio Petroleum Corp (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, today provided an update […]

Trio Petroleum Corp (NYSE American: TPET) Announces an Option to Acquire a 20% Interest in the Asphalt Ridge Development Project in Utah

Estimated Contingent Resources of 42-92 Million Barrels of Oil Development of this Potential Giant Oilfield Commencing January 2024 Bakersfield, CA, Jan. 05, 2024 (GLOBE NEWSWIRE) — Trio Petroleum Corp (NYSE American: TPET) (“Trio” or the “Company”), a California-based oil and gas company, today announced that it has secured an option (the “Option”) to acquire a 20% interest […]

Tiziana Life Sciences (Nasdaq: TLSA) Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity – Associated Inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today announced filing of a new patent application relating to composition and methods for combining GLP-1ra and foralumab, a fully human anti-CD3 antibody, to achieve further reductions in systemic and vascular inflammation […]

CBOE-Listed SinglePoint Inc. (CBOE: SING) Provides Strategic Overview, Highlights Milestones Reached, and Expectations In 2024

Phoenix, Arizona—(Newsfile Corp. – January 5, 2024) – SinglePoint Inc. (CBOE: SING) (“SinglePoint” or “the Company”), a provider of renewable energy, energy supply, and healthy building solutions, provides an update highlighting 2023 accomplishments and its plans to increase shareholder value in 2024. After successfully listing on the CBOE BZX Exchange in December, SinglePoint enters the […]

NanoViricides (NYSE American:NNVC) to Present at the Biotech Showcase in San Fransisco

SHELTON, CT / ACCESSWIRE / January 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it is presenting at Biotech Showcase™ 2024. Event Information: Event NanoViricides Presentation at the Biotech Showcase, San Fransisco Day & Date Tuesday, January 9, […]

SciSparc (Nasdaq: SPRC) and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

The collaboration included six different provisional patent applications filed by Clearmind with the United States Patent and Trademark Office in February 2023 to protect the novel combinations of psychedelics with SciSparc’s PEA TEL AVIV, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) —  SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on […]

Start Expanding
Your Shareholder Base

Let us help you connect with investors
committed to your success.